ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1212

Investigation of Vitamin D Supplement Use, Rheumatoid Arthritis-Related Autoimmunity and Joint Signs Among Those at Increased Risk for the Development of Rheumatoid Arthritis

Elizabeth A. Bemis1, Ryan W. Gan2, Marie L. Feser3, Michael H. Weisman4, James R. O'Dell5, Ted R. Mikuls5, Jane H. Buckner6, Peter K. Gregersen7, Richard M. Keating8, M. Kristen Demoruelle9, Kevin D. Deane10, V. Michael Holers11 and Jill M. Norris12, 1Epidemiology, Epidemiology, Colorado School of Public Health, Aurora, CO, 2Colorado School of Public Health, University of Colorado Denver, Aurora, CO, 3Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 4Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 5University of Nebraska Medical Center, Omaha, NE, 6Benaroya Research Institute at Virginia Mason, Seattle, WA, 7Feinstein Insititute for Medical Research, Manhasset, NY, 8Division of Rheumatology, Scripps Health, La Jolla, CA, 9Rheumatology, University of Colorado School of Medicine, Aurora, CO, 10Division of Rheumatology, U Colo Denver, Aurora, CO, 11Rheumatology Division, Univ of Colorado School of Med, Aurora, CO, 12University of Colorado Denver, Aurora, CO

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: autoantibodies and rheumatoid arthritis (RA), Vitamin D

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Epidemiology and Public Health Poster II: Pathogenesis and Treatment of Systemic Inflammatory Diseases

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:
Vitamin D has immunomodulatory
properties, and could be a protective factor against rheumatoid arthritis (RA).
Anti-cyclic citrullinated peptide (anti-CCP)
autoantibodies and swollen small joints of the hand (wrist and metacarpophalangeal [MCP] joints) are characteristics of RA
that can be present years prior to the development of classifiable RA by
established criteria. We investigated the associations between anti-CCP2
positivity and swollen joint symptoms with self-reported vitamin D supplement
use in a population without RA, but at risk for development of RA.

Methods:   The
multicenter Studies of the Etiology of RA (SERA) cohort study recruited
subjects who are classified as RA-free at visit, but at increased genetic
and/or family risk for RA. At baseline, we assessed the association between
self-reported vitamin D supplement use over the past year and presence of the
two preclinical outcomes, anti-CCP2 positivity and having >= 1 swollen wrist and/or MCP joint. Three vitamin D exposure
variables were created including a yes or no response, source of vitamin D
(none, multivitamin or single supplement), and total months of use (0 months,
1-12 months or >12 months [i.e. those taking more than one vitamin D supplement]).
These self-reported variables were found to be associated with 25-hydroxyvitamin D (25OHD) plasma concentrations that were available in a subset of the study population. Logistic
regression models were used to estimate the independent association between the
three exposure variables and the two outcomes, adjusting for age, sex, race,
shared epitope, current smoking, cohort (first degree relative vs not), site of recruitment and use of other supplements.

Results: The analysis cohort (n=2,383 at-risk subjects) was 69% female, 80% non-Hispanic white, with a mean age
of 44.6 years. We identified 44 anti-CCP2 subjects and 57 subjects
with
>= 1 swollen joint at baseline. 
Vitamin D supplement use was not associated with anti-CCP2 positivity
(Table). A marginally significant association was seen with joint signs, where
those with
>= 1 swollen joint were about half as likely to have been taking
vitamin D supplements in the previous year (Table).

Table: Odds ratios (OR) for anti-CCP2 positivity and >=1 swollen joint in relation to each vitamin D exposure variable.

Outcome

Anti-CCP2

n=44 positive subjects

>= 1 swollen joint*

n=57 positive subjects

Any Vitamin D Supplement

OR (95% CI)

p-value

OR (95% CI)

p-value

No

1.00

Ref

1.00

Ref

Yes

1.92 (0.47-7.92)

0.37

0.47 (0.22-1.01)

0.07

Vitamin D Source

No vitamin D supplement

1.00

Ref

1.00

Ref

From a Multivitamin only

1.80 (0.43-7.55)

0.42

0.47 (0.22-1.04)

0.08

From a Single supplement containing vitamin D

2.37 (0.49-11.43)

0.28

0.47 (0.17-1.32)

0.19

Vitamin D Duration

0 Months (no vitamin D supplement)

1.00

Ref

1.00

Ref

1-12 Months

1.15 (0.26-5.05)

0.85

0.46 (0.22-1.05)

0.07

>12 Months

2.45 (0.46-13.08)

0.29

0.45 (0.14-1.38)

0.16

Adjusted for age, sex, race, cohort, recruitment site, current smoking status, Shared Epitope, and other supplement use.

*The sample size for the joint outcome analysis is n=1955, which is reduced because our off-site visits did not include a joint examination.

Conclusion: Vitamin D supplement use was not associated with RA-related
autoimmunity in at-risk subjects. An inverse trend between joint signs and
vitamin D supplement use suggests the need for further research to examine the
role of vitamin D in the later stages of pre-clinical RA.


Disclosure: E. A. Bemis, None; R. W. Gan, None; M. L. Feser, None; M. H. Weisman, None; J. R. O'Dell, None; T. R. Mikuls, None; J. H. Buckner, None; P. K. Gregersen, Illumina Inc., 1,Janssen Pharmaceutica Product, L.P., 5,Biogen, Idec, 5; R. M. Keating, None; M. K. Demoruelle, None; K. D. Deane, None; V. M. Holers, Shared patent with Stanford University for use of biomarkers to predict clinical phenotypes in rheumatoid arthritis., 7; J. M. Norris, None.

To cite this abstract in AMA style:

Bemis EA, Gan RW, Feser ML, Weisman MH, O'Dell JR, Mikuls TR, Buckner JH, Gregersen PK, Keating RM, Demoruelle MK, Deane KD, Holers VM, Norris JM. Investigation of Vitamin D Supplement Use, Rheumatoid Arthritis-Related Autoimmunity and Joint Signs Among Those at Increased Risk for the Development of Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/investigation-of-vitamin-d-supplement-use-rheumatoid-arthritis-related-autoimmunity-and-joint-signs-among-those-at-increased-risk-for-the-development-of-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/investigation-of-vitamin-d-supplement-use-rheumatoid-arthritis-related-autoimmunity-and-joint-signs-among-those-at-increased-risk-for-the-development-of-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology